LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea

Contributed by: Business Wire

Logo

Tags

General Health

Health Technology

Health

Medical Devices

Sleep apnea

More Like This

Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting

LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea

LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance

LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day